[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100461307":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":49,"collaborators":20,"id":52,"slug":20,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":20,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":20,"enrollmentInfo":61,"targetDuration":20,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"University of Washington","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"N. gonorrhea (gyrA wildtype) -Ciprofloxacin Treatment Arm","EXPERIMENTAL","Participants who are N. gonorrhea (NG) positive and gyrA WT, will receive ciprofloxacin 500 mg PO x 1.",[13],"Drug: Ciprofloxacin 500 mg",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Ciprofloxacin 500 mg","Ciprofloxacin 500 MG, taken once orally.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Lindley Barbee, MD, MPH","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Angela LeClair","CONTACT","206-744-0489","achein@uw.edu",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Public Health -- Seattle & King County Sexual Health Clinic","RECRUITING","Seattle","Washington","98104","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-122.33207,47.60621,{"lat":44,"lon":43},[47],{"name":48,"role":28,"phone":20,"phoneExt":20,"email":20},"Angela LeClair, ND",{"type":24,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Lindley Barbee","Associate Professor: School of Medicine Allergy and Infectious Diseases","100461307",false,"NCT05286931","SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection","Evaluation of SpeeDx's Ciprofloxacin gyrA Assay for Clinical Care of STD Clinic Patients With Neisseria Gonorrhea","Inclusion Criteria:\n\n* English speaking\n* Have access to the internet (via computer or phone) on at least a weekly basis\n* Asymptomatic (as defined below)\n\nExclusion Criteria:\n\n* Urogenital symptoms consistent with a sexual transmitted infection (other than vaginitis associated with trichomonas vaginalis, bacterial vaginosis or yeast). Symptoms consistent with cervicitis, urethritis, or PID will not be offered enrollment.\n* Antibiotic use within the last 2 weeks\n* Contact to syphilis\n* Contact to an STI and are unwilling to defer empiric treatment until diagnostic test results return\n* Anyone receiving a gonococcal-active drug (such as Doxycycline, Penicillin, Ceftriaxone) during the visit. Those receiving metronidazole, fluconazole, or clotrimazole will not be excluded.\n* Known allergy to ciprofloxacin and\u002For ceftriaxone",true,"ALL","18 Years",{"count":62,"type":63},1800,"ESTIMATED","INTERVENTIONAL",[66],"NA","This study aims to test the effectiveness of using of SpeeDx Resistance Plus assay to guide treatment of Neisseria gonorrhoeae (Ng) in a sexual health clinic setting.",[69],"Neisseria Gonorrhoeae Infection",[71,72,73],"antimicrobial resistance","ciprofloxacin","molecular diagnostics","2022-03-09",{"date":76,"type":77},"2022-03-18","ACTUAL",{"date":79,"type":77},"2022-03-03",{"date":81,"type":63},"2026-12-31",{"name":5,"class":6},1]